Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29861646 | 1.00 | BTK (0.46) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL25126894 | 1.00 | BTK (0.46) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL21621824 | 1.00 | BTK (0.46) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL30059450 | 1.00 | BTK (0.46) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL21238714 | 0.89 | BTK (0.51) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL21423769 | 0.89 | BTK (0.47) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL22242735 | 0.89 | BTK (0.51) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL1670964 | 0.89 | BTK (0.47) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL6525816 | 0.89 | BTK (0.51) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL19578680 | 0.89 | BTK (0.51) | BTKNFKB1NFKB2RELACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371562-A2 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-3630749-B1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-20230019732-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-19 | — | — | US | disclosed |
| US-11161839-B2 | 2-quinolone derived inhibitors of BCL6 | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210206756-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-08 | — | — | US | disclosed |
| CN-112261970-A | 3- (5-hydroxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family Zinc finger 2(IKZF2) dependent diseases | 诺华股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-3630749-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215798-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
| EP-2007754-A1 | 2, 4-DIAMINOPYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007115999-A1 | 2, 4-DIAMINOPYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019732-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | BTK 122/4885NFKB1 1843/4885NFKB2 1140/4885 |
| US-11161839-B2 | 2-quinolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | BTK 204/4885NFKB1 99/4885NFKB2 102/4885 |
| US-20210206756-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | BTK 204/4885NFKB1 99/4885NFKB2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.